Hereditary Angioedema

Companies sign manufacturing agreement for recombinant human C1 inhibitor

Published in Gene Therapy Weekly, March 10th, 2005

Diosynth, BV, and Pharming Group, NV, announced a supply agreement for the production of recombinant human C1 inhibitor (rhC1INH) for commercial use.

This agreement enables Pharming to prepare for the market launch of rhC1INH for the treatment of hereditary angioedema, a life-threatening genetic disorder caused by a deficiency of the C1 inhibitor protein. Pharming has obtained an orphan drug designation from the U.S. Food and Drug Administration (FDA) and European Medicines Evaluation Agency for rhC1INH in treatment of hereditary as well as acquired form of angioedema.

Under the agreement, Akzo Nobel's Diosynth Biotechnology business is responsible...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry